

Joseph Fontana

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9014290/publications.pdf>

Version: 2024-02-01

11
papers

401
citations

932766

10
h-index

1372195

10
g-index

11
all docs

11
docs citations

11
times ranked

589
citing authors

#	ARTICLE	IF	CITATIONS
1	Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locally advanced prostate cancer. <i>Urology</i> , 2003, 61, 774-780.	0.5	106
2	Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy. , 2017, 5, 82.		77
3	A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer. <i>BJU International</i> , 2007, 100, 765-769.	1.3	61
4	Neoadjuvant estramustine and etoposide followed by concurrent estramustine and definitive radiotherapy for locally advanced prostate cancer: Feasibility and preliminary results. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 49, 699-703.	0.4	33
5	An active regimen of weekly paclitaxel and estramustine in metastatic androgen-independent prostate cancer. <i>Urology</i> , 2002, 60, 1050-1054.	0.5	32
6	A single institution experience with concurrent capecitabine and radiation therapy in weak and/or elderly patients with urothelial cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 62, 1332-1338.	0.4	26
7	Phase II trial of bevacizumab and satraplatin in docetaxel-pretreated metastatic castrate-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 31.e25-31.e33.	0.8	16
8	Preclinical efficacy evaluations of XK-469: dose schedule, route and cross-resistance behavior in tumor bearing mice. <i>Investigational New Drugs</i> , 2002, 20, 13-22.	1.2	15
9	Pilot Phase II Trial of Bevacizumab Monotherapy in Nonmetastatic Castrate-Resistant Prostate Cancer. <i>ISRN Oncology</i> , 2012, 2012, 1-7.	2.1	12
10	Phase I Trial of the Combination of Docetaxel, Prednisone, and Pasireotide in Metastatic Castrate-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e695-e703.	0.9	12
11	Phase II Trial of Estramustine and Etoposide in Androgen-Sensitive Metastatic Prostate Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2004, 27, 550-554.	0.6	11